Open AccessDipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
Author(s) -
Sekizaki Tomonori,
Kameda Hiraku,
Nomoto Hiroshi,
Cho Kyu Yong,
Nakamura Akinobu,
Takahashi Kiyohiko,
Miyoshi Arina,
Wada Norio,
Takeuchi Jun,
Nagai So,
Miyoshi Hideaki,
Atsumi Tatsuya
Publication year - 2021
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.13578
Subject(s) - medicine , exacerbation , dipeptidyl peptidase 4 , observational study , dipeptidyl peptidase 4 inhibitor , diabetes mellitus , odds ratio , dipeptidyl peptidase , gastroenterology , type 2 diabetes , pharmacology , endocrinology , biochemistry , chemistry , enzyme
Dipeptidyl peptidase‐4 (DPP‐4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP‐4 might affect the immune system. The current multicenter observational case–control study was carried out to investigate the effects of DPP‐4 inhibitor (DPP‐4i) administration on Graves' disease (GD) activity. This study comprised patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP‐4i. Exacerbation of GD was defined as an increase of antithyroid drug dose by 6 months after oral hypoglycemic agent administration. A total of 80 patients were enrolled and divided into an exacerbation group or a non‐exacerbation group. The frequency of DPP‐4i administration was significantly higher in the exacerbation group (88%) than that in the non‐exacerbation group (31%). In multivariate logistic regression analysis, there was a significant association between DPP‐4i administration and GD exacerbation (odds ratio 7.39). The current study suggests that DPP‐4i administration is associated with GD exacerbation.